Monepantel Phase 2 Study Results
PharmAust has announced positive top-line data from its Phase 2 veterinary clinical study of monepantel (MPL) for the treatment of Canine B-Cell Lymphoma. The company plans to use this data to open an Investigational New Animal Drug (INAD) application with the United States Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) and proceed with studies in 2024 to support product registration.
Pet Cancer Information Service
Promising Clinical Study for Dogs with Lymphoma – for this and any other information regarding advice for pets with cancer, please contact Dr. Catherine Chan: